+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the consistency of immune responses to three different batches of an investigational chickenpox vaccine called VNS vaccine in healthy children aged 12 to 15 months who have not had chickenpox or received a chickenpox vaccine before. The study also compares the safety and immune response of the VNS vaccine to an approved chickenpox vaccine known as Varivax. This Phase 3a study is sponsored by GlaxoSmithKline and aims to better understand the immune protection provided by these vaccines. Participants are randomly assigned to receive one dose of either one of the three investigational VNS vaccine lots or one of two lots of the marketed Varivax vaccine. Along with the chickenpox vaccine, they also receive one dose each of measles, mumps, and rubella MMR vaccine, hepatitis A vaccine HAV, and a pneumococcal conjugate vaccine PCV which could be PCV 13, Vaxneuvance, or PCV 20 depending on availability and country recommendations. All vaccines are given on Day 1 of the study. During the study, researchers monitor the participants immune responses by measuring antibodies against varicella zoster virus VZV and other vaccine components at Day 43. They also track safety by recording any side effects or adverse events from Day 1 to Day 181. The study includes diary reports by parents and regular clinical evaluations to assess immune response and safety outcomes. Participation involves a single vaccination visit and follow-up assessments over approximately six months.

Age: 12Months - 15MonthsAll GendersPhase 3
97 locations
P

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the immune response and safety of an investigational chickenpox vaccine VNS Vaccine compared to an already approved vaccine called Varivax VV. The study focuses on healthy children who have not previously had chickenpox or received a chickenpox vaccine, and takes place when the second dose is given three months after the first dose, which is administered between 12 and 15 months of age. Participants are randomly assigned to one of three groups one group receives two doses of the Varivax vaccine another group receives two doses of the investigational VNS vaccine and the third group receives a first dose of Varivax followed by a second dose of the VNS vaccine. Additional vaccines including measles, mumps, and rubella MMR, hepatitis A HAV, and pneumococcal conjugate vaccine PCV are given on the first day. In some countries, a second dose of MMR is also given between 15 and 18 months according to national guidelines. During the study, researchers will monitor immune responses by measuring specific antibodies against the chickenpox virus after the second dose, particularly 43 days post-vaccination. They will also track any local or systemic side effects following each vaccine dose, recording adverse events up to nearly nine months after the first dose. The total participation includes multiple visits over this time, ensuring detailed safety and immune response assessment for each child.

Age: 12Months - 15MonthsAll GendersPhase 3
6 locations
P

Actively Recruiting

Researchers are studying the effectiveness and safety of Afimkibart as an induction and maintenance treatment for people with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to evaluate how well Afimkibart works compared to a placebo in managing this condition. Participants will be randomly assigned to receive either Afimkibart or a placebo. Those receiving Afimkibart will get an intravenous IV infusion followed by subcutaneous SC injections. The study includes two experimental groups receiving Afimkibart and one group receiving placebo, both administered by IV and SC methods. The treatment and follow-up period extends through 52 weeks to assess both induction and maintenance therapy effects. During the study, participants will undergo evaluations including the Crohns Disease Activity Index CDAI for clinical remission and endoscopic assessments at week 52. Additional measurements at week 12 and throughout the study include symptom tracking, stool frequency, abdominal pain, quality of life questionnaires, and monitoring of adverse events. The total study duration may extend up to 70 weeks for safety follow-up and outcome assessments.

Age: 16Years - 80YearsAll GendersPhase 3
375 locations
E

Actively Recruiting

Researchers are conducting a Phase 2 trial to compare TP-06 2.0% ophthalmic solution with a placebo vehicle in adults who have persistent corneal epithelial defects PCED that have not healed after at least 10 days of standard treatment. This trial aims to evaluate the safety and effectiveness of TP-06 in promoting corneal healing, improving visual acuity, and assessing changes in corneal thickness. Participants will be randomly assigned to receive either TP-06 2.0% or the vehicle four times daily for 8 weeks, alongside required background therapy. After the treatment phase, there will be a 2-week follow-up period to monitor healing and safety. The study is double-masked and involves multiple centers. During the study, participants will undergo assessments including evaluation of corneal healing through fluorescein staining, measurement of lesion size with imaging, and tests of visual acuity. Researchers will monitor the timing and extent of corneal healing and any safety concerns. The total participation time includes 8 weeks of treatment plus 2 weeks of follow-up.

Age: 18Years +All GendersPhase 2
14 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.

Age: 16Years - 80YearsAll GendersPhase 3
499 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating two dose levels of mRNA-1283 in children aged 6 months to less than 12 years to find the best dose for each age group. The study is a phase 2, randomized, observer-blind trial comparing mRNA-1283 with mRNA-1273 as an active comparator. It aims to assess safety, immune response, and side effects related to these vaccines against SARS-CoV-2. The study includes two cohorts Cohort 1 involves children aged 2 to less than 12 years receiving a single intramuscular dose of either mRNA-1283 at Dose Level 1 or Dose Level 2, or mRNA-1273. Cohort 2 includes children aged 6 months to less than 2 years who are unvaccinated against COVID-19 and receive two intramuscular doses 28 days apart of either mRNA-1283 at Dose Level 1 or Dose Level 2, or mRNA-1273. The study compares the immune responses and side effects between these groups. Participants will be monitored for local and systemic adverse reactions for 7 days after vaccination and unsolicited adverse events for up to 28 days. Serious and medically attended adverse events will be tracked throughout the study, which lasts up to 13 months. Researchers will measure antibody levels against SARS-CoV-2 at specific visits to evaluate immune response. The trial includes regular medical evaluations and safety assessments to ensure participant well-being.

Age: 6Months - 11YearsAll GendersPhase 2
31 locations
E

Actively Recruiting

Researchers are evaluating whether using the Dexcom G7 continuous glucose monitor intermittently, alongside pediatric endocrinology check-ups, diabetes education, and psychological support, can improve blood sugar control in children and adolescents aged 10 to 19 with high-risk type 1 diabetes in the Dominican Republic. This pilot longitudinal study involves 40 participants from two pediatric diabetes care centers to understand better glucose management in this group. Participants will use the Dexcom G7 device during two separate short monitoring periods early in the study, using a total of six sensors. Between and after these periods, they will return to their usual finger-stick glucose monitoring. Alongside device use, participants and their families will attend regular medical visits, education sessions, and psychological support meetings to support diabetes management. Throughout the study, researchers will collect information from medical records, lab results, Dexcom reports, glucose logs, study forms, and questionnaires. They will measure changes in HbA1c, time spent in target glucose range, average glucose levels, glucose variability, episodes of low and high blood sugar, adverse events, diabetes-related distress, fear of hypoglycemia, and satisfaction with glucose monitoring. The study will last over 12 months with scheduled follow-ups every 2 weeks for the first 3 months and then monthly visits until study completion.

Age: 10Years - 19YearsAll Genders
3 locations
S

Actively Recruiting

Researchers are studying pediatric participants aged 4 weeks to less than 12 years with human immunodeficiency virus type 1 HIV-1 infection, weighing under 45 kg. The study focuses on treatment-naive children or those virologically suppressed on stable combination antiretroviral therapy for at least 3 months without treatment failure. The main goals are to evaluate the steady-state pharmacokinetics, safety, and tolerability of doravirine DOR when given with two nucleosidenucleotide reverse transcriptase inhibitors NRTIs or as part of the fixed-dose combination FDC of DORlamivudinetenofovir disoproxil fumarate DOR3TCTDF in children aged 6 to less than 12 years weighing 14 to less than 45 kg. Participants receive oral doravirine doses ranging from 7.2 mg to 100 mg based on weight, combined with two NRTIs according to local guidelines, or the fixed-dose combination DOR3TCTDF, for a treatment period of 96 weeks. Those completing the Week 96 visit may join an extension study to receive doravirine for up to an additional 224 weeks or until commercial availability. The study is open-label and conducted across multiple sites. During the study, participants undergo intensive pharmacokinetic sampling at designated times up to 24 hours postdose to measure doravirine levels in plasma. Researchers also monitor safety outcomes up to 24 weeks and additional secondary outcomes including viral load, CD4 T-cell counts, adverse events, adherence, and palatability of the oral pellets or granules. Assessments continue through Week 96, with close monitoring of viral suppression, drug resistance, and tolerability throughout the study and extension period.

Age: 4Weeks - 11YearsAll GendersPhase 2
26 locations
S

Actively Recruiting

Researchers are conducting an international, multicenter observational study to understand acute kidney injury requiring renal replacement therapy AKI-RRT in Latin American countries. The study focuses on the epidemiology, outcomes, and care processes for patients with AKI-RRT, comparing variations across different countries and examining factors such as demographics, clinical profiles, and socioeconomic status that may influence patient outcomes. The aim is to establish a comprehensive database to support clinical research and improve understanding of AKI-RRT in this region. The study observes critically ill adult patients admitted to intensive care units ICUs who are undergoing any form of renal replacement therapy. It collects detailed clinical, laboratory, treatment, and outcome data without assigning treatments, as it is observational. Patients are followed from enrollment through hospital discharge or up to 90 days, including ICU stay and 90-day post-ICU follow-up to track mortality, renal recovery, and complications related to renal replacement therapy. Participants involvement includes monitoring during ICU and hospital stays with data collected on mortality rates, length of stay, renal function recovery, dependence on renal replacement therapy, and complications such as infections or anticoagulation issues. The primary outcome measured is in-hospital mortality, with secondary outcomes covering ICU mortality, 90-day mortality, length of stay, recovery, and procedural complications. This study spans from enrollment until 90 days after ICU admission, providing extensive observational data on AKI-RRT in Latin America.

Age: 18Years +All Genders
15 locations
I

Actively Recruiting

Researchers are observing patients with Gaucher disease in the International Collaborative Gaucher Group ICGG Gaucher Registry to understand the diseases variability, progression, and natural history. The study aims to help guide treatment decisions and improve patient care by providing data on patient outcomes and the long-term effectiveness of treatments like imiglucerase and eliglustat. There is also a Gaucher Pregnancy Sub-registry focusing on pregnancy outcomes and infant growth in women with Gaucher disease. Participants in the Registry do not receive experimental treatments but continue with their usual clinical assessments and care as determined by their physicians. The Pregnancy Sub-registry collects data from pregnant women with Gaucher disease, including medical and obstetric history, pregnancy, birth details, and infant growth up to 36 months postpartum. Both registries do not involve any experimental interventions and support standard care practices. During the study, participants undergo routine clinical assessments and provide medical data as part of their ongoing care. Data collected includes patient outcomes, monitoring recommendations, and pregnancy-related information when applicable. The studys primary outcomes include generating monitoring guidelines for Gaucher disease and tracking pregnancy and infant growth outcomes. The registry is ongoing and international, with data collected over several decades to enhance understanding and optimize care for Gaucher disease.

All AgesAll Genders
317 locations

1-10 of 12

1